Phibro Animal Health CEO Reduces Stake in $1.2 Million Share Sale

Jack Bendheim, President and CEO of Phibro Animal Health Corporation (PAHC), has completed the indirect sale of 21,120 shares of common stock. The transactions, executed between April 21 and April 23, 2026, were conducted via BFI Co. LLC, an entity over which Bendheim maintains voting and dispositive control. The sale, valued at approximately $1.16 million based on a weighted average price of $54.79 per share, represents roughly 15.78% of Bendheim's prior holdings. However, the divestment appears to be a routine portfolio adjustment, as the CEO retains a substantial stake of over 100,000 shares in the animal health provider. Phibro's recent financial performance remains robust, driven largely by the 2024 acquisition of Zoetis' medicated feed additive (MFA) business. In the second fiscal quarter, the company reported a 21% year-over-year increase in sales to $373.9 million. Net income saw a significant jump to $27.5 million, compared to $3.2 million in the same period last year, with adjusted net income rising 60%. Based on strong performance across all operating segments, management has upwardly revised its fiscal 2026 guidance. The company now projects sales growth of approximately 14% and a net income increase of 86% at the midpoint of its guided ranges.